Lysine demethylases (KDMs) are epigenetic regulators whose dysfunction is implicated in the pathology of many human diseases including various types of cancer, inflammation and X-linked intellectual disability. Particular demethylases have been identified as promising therapeutic targets, and tremendous efforts are being devoted toward developing suitable small-molecule inhibitors for clinical and research use. Several high-throughput screening strategies have been developed to screen for small-molecule inhibitors of KDMs, each with advantages and disadvantages in terms of time, cost, effort, reliability and sensitivity. In this Special Report, we review and evaluate the high-throughput screening methods utilized for discovery of novel small-molecule KDM inhibitors.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 44 条
[1]
Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383
机构:
Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USAUniv Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA
Hou, Haifeng
;
Yu, Hongtao
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USAUniv Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA
机构:
Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USAUniv Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA
Hou, Haifeng
;
Yu, Hongtao
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USAUniv Texas SW Med Ctr Dallas, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA